

ASX ANNOUNCEMENT
ECS Botanics Holdings Ltd (ASX:ECS)
14 February 2022



ECS makes first dried cannabis flower shipment to the United Kingdom

- **Successful completion of first international export of ECS' Australian grown dried cannabis flower**
- **ECS supplying to Lyphe Group, the UK's largest Patient First Medical Cannabis company**
- **Shipment partially fulfills received purchase orders totalling over \$500,000, to be delivered as current harvest becomes available now and over the coming months**
- **Strong demand for ECS dried cannabis flower in the UK an indication of the Company's quality and competitive pricing**
- **Strong growth in the UK and Europe expected to materialise this calendar year**

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading medicinal cannabis and hemp company, is pleased to report it has successfully completed its first shipment of dried cannabis flower to Lyphe Group ("Lyphe"), the largest distributor of medicinal cannabis in the UK.

ECS has received purchase orders from Lyphe for the UK market for dried cannabis flower totalling over \$500,000. These will be delivered over the coming months as product becomes available from the current harvest. ECS is working closely with Lyphe and expecting further orders over CY2022.

Lyphe delivers a patient-focused medical cannabis ecosystem, and has emerged as the UK's market leader in patient care, seeing over 60% of the medical cannabis patients in the country. Lyphe delivers a reliable and seamless supply of medical cannabis care and medicine. It has built a patient-access ecosystem across the UK that provides clinics, pharmacy and dispensing, import infrastructure, and vital educational services to patients, doctors and other health care professionals.

ECS expects that the UK and Europe will become a significant market for the Company during 2022 and 2023, as demand increases for its high quality and competitively priced GMP certified products. ECS is currently performing additional ICH stability testing, required for product registration in many EU markets, expected to be complete within the next 6 months.

Managing Director Alex Keach said: *"This shipment is a significant milestone for ECS, as it is the first international export of our Australian grown dried cannabis flower. We expect our product to be well received by patients in the UK, and demand for our flower to grow significantly through the year."*

Chief Commercial Officer of Lyphe, Chris Ashton said: *"I'm delighted our importer is in receipt of the first shipment of ECS manufactured medical cannabis flowers. The range and quality of products offered by ECS represents a significant improvement in the UK supply chain and I'm sure will be well received by all UK patients. I'm looking forward to receiving the further products we have on order and excited to expand this partnership to support the demand from UK patients"*

-ENDS-



About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd is a leading medicinal cannabis and hemp business. The Company owns farms and medicinal cannabis facilities in Tasmania and Victoria for the cultivation, processing, and manufacturing of medicinal cannabis. ECS manufactures to EU GMP standards and also has the necessary licences and partnerships to cultivate and manufacture a range medicinal cannabis oil and dry flower products. ECS has a hemp food and wellness business, supplying both the wholesale and retail market across Australia. ECS' core focus is scale and low-cost production, without compromising quality.

For further information, please contact:

Alexander Keach, Managing Director

info@ecs-botanics.com

Authorised on behalf of ECS by Alex Keach, Managing Director